29 June 2022 | Wednesday | News
Image Source : Public Domain
The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/m3.Currently, WuXi STA has two sites located in Shanghai Jinshan and Changzhou, China to support the process development and manufacture of high-potency active pharmaceutical ingredients.
These two facilities are equipped with multiple HP process R&D and analytical labs, kilo labs, and three plants along with process technologies such as prep-HPLC, milling, flow chemistry etc, providing customers a dual supply chain to meet their HPAPI needs from preclinical to commercial.
In addition to HP API, WuXi STA’s Changzhou site is capable of handling the process development and manufacturing services for linkers, oligonucleotides, and peptides, providing a unique “one-stop” flexible and efficient solution to companies developing therapies made of various complex conjugate modalities.
As an industry-leading CRDMO service provider, WuXi STA is committed to continuously adding new capabilities and capacities to our global network to support our global partners by accelerating more innovative therapies to patients worldwide.